ArticleFrontiers in immunology2026
Integrated multi-omics profiling reveals immune-related biomarkers and regulatory networks for early prediction of tuberculosis in type 2 diabetes mellitus.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes mellitus (T2DM) significantly elevates the risk of tuberculosis (TB); however, early detection in T2DM patients is still insufficient. This study aimed to identify immune-based early-warning biomarkers, develop robust prognostic models, and elucidate the immune-metabolic circuitry underlying the comorbidity of type 2 diabetes and tuberculosis (T2DM-TB). Methods: A prospective cohort study (n = 198; HC 71, T2DM 67, T2DM-TB 60) was conducted, involving whole-transcriptome and plasma-proteome profiling. Differential expression analysis, weighted gene co-expression network analysis (WGCNA), and mining of the ImmPort database facilitated the extraction of immune-relevant genes. Protein-protein interaction (PPI) and competing endogenous RNA (ceRNA) networks were utilized to delineate core regulators. Eleven logistic regression models were developed based on 13 cross-platform biomarkers. The robustness of these models was evaluated through 5-fold cross-validation, and feature selection was optimized using least absolute shrinkage and selection operator (LASSO) regression. External validation was performed using GEO datasets (GSE181143, GSE114192) and reverse transcription quantitative polymerase chain reaction (RT-qPCR). Functional annotation and xCell immune-infiltration analyses were employed to characterize microenvironmental shifts, while dual-luciferase assays confirmed ceRNA interactions. Results: Thirteen immune-related biomarkers were identified, comprising 4 mRNAs (IRF1, FPR1, LILRB3, SECTM1), 2 microRNAs (miRNAs) (hsa-miR-4726-5p, novel-miR-109), 3 long non-coding RNAs (lncRNAs) (MSTRG.128052.1, MSTRG.4908.1, MSTRG.37670.90), and 4 proteins (IFN-γ, IL-6, CXCL10, CXCL6). Eleven models demonstrated high diagnostic efficacy, with area under the curve (AUC) values ranging from 0.93 to 0.99, and exhibited stable performance in 5-fold cross-validation, yielding AUC values between 0.77 and 0.95. LASSO-derived concise biomarker subsets overlapped with primary model features, thereby confirming robust discriminative stability. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses underscored the significance of immune response, inflammation, and metabolic regulation, highlighting key pathways such as Toll-like receptors, NF-κB, and JAK-STAT. Immune infiltration analysis revealed a "pro-inflammatory-suppressive-reconstructive" imbalance characterized by overactivated innate immunity, including M1/M2 macrophages and NKT cells, alongside compromised adaptive immunity, evidenced by reduced CD4⁺/CD8⁺ T cells and B cells. Additionally, ceRNA networks and dual-luciferase assays confirmed that novel-miR-109 inhibits the translation of FPR1, LILRB3, and MSTRG.4908.1, while hsa-miR-4726-5p targets the 3' UTR of SECTM1. Conclusions: This study establishes a validated multi-omics framework for the early detection of T2DM-TB, elucidates key regulatory axes (IRF1/IFN-γ, ceRNA circuitry, CXCL10/CXCL6), and provides actionable biomarkers and high-performance models for precision intervention in T2DM-TB management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.